Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
Iterum Therapeutics Trading Down 3.1%
NASDAQ:ITRM opened at $0.72 on Friday. The company has a market capitalization of $33.96 million, a P/E ratio of -0.85 and a beta of 3.04. Iterum Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.02. The firm has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $0.96.
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). Equities analysts forecast that Iterum Therapeutics will post -0.86 EPS for the current year.
Institutional Inflows and Outflows
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Read More
- Five stocks we like better than Iterum Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Healthcare Stocks Using AI to Drive Growth
- The 3 Best Fintech Stocks to Buy Now
- Get Exposure to Millennials’ Purchasing Power With This ETF
- 3 REITs to Buy and Hold for the Long Term
- Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI Ambitions
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
